Search Results - "Morgan, Gareth J."

Evolutionary biology of high-risk multiple myeloma by Pawlyn, Charlotte, Morgan, Gareth J.

“…Key Points Treatment of myeloma has developed rapidly over the past two decades with the advent of proteasome inhibitors and immunomodulatory agents. Despite…”
Get full text

The genetic architecture of multiple myeloma by Morgan, Gareth J., Walker, Brian A., Davies, Faith E.

“…Key Points The initiation of myeloma is mediated by the interaction of environmental factors and inherited genetic events that, when combined with the normal…”
Get full text

Barriers to Small Molecule Drug Discovery for Systemic Amyloidosis by Morgan, Gareth J

“…Inhibition of amyloid fibril formation could benefit patients with systemic amyloidosis. In this group of diseases, deposition of amyloid fibrils derived from…”
Get full text

The Kinetic Stability of a Full-Length Antibody Light Chain Dimer Determines whether Endoproteolysis Can Release Amyloidogenic Variable Domains by Morgan, Gareth J., Kelly, Jeffery W.

“…Light chain (LC) amyloidosis (AL amyloidosis) appears to be caused by the misfolding, or misfolding and aggregation of an antibody LC or fragment thereof and…”
Get full text

Curing myeloma at last: defining criteria and providing the evidence by Barlogie, Bart, Mitchell, Alan, van Rhee, Frits, Epstein, Joshua, Morgan, Gareth J., Crowley, John

“…Does the dogma that multiple myeloma is incurable still hold?. The genomic chaos and resulting resistance to apoptosis of myeloma, long considered an obstacle…”
Get full text

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma by Walker, Brian A., Mavrommatis, Konstantinos, Wardell, Christopher P., Ashby, T. Cody, Bauer, Michael, Davies, Faith E., Rosenthal, Adam, Wang, Hongwei, Qu, Pingping, Hoering, Antje, Samur, Mehmet, Towfic, Fadi, Ortiz, Maria, Flynt, Erin, Yu, Zhinuan, Yang, Zhihong, Rozelle, Dan, Obenauer, John, Trotter, Matthew, Auclair, Daniel, Keats, Jonathan, Bolli, Niccolo, Fulciniti, Mariateresa, Szalat, Raphael, Moreau, Philippe, Durie, Brian, Stewart, A. Keith, Goldschmidt, Hartmut, Raab, Marc S., Einsele, Hermann, Sonneveld, Pieter, San Miguel, Jesus, Lonial, Sagar, Jackson, Graham H., Anderson, Kenneth C., Avet-Loiseau, Herve, Munshi, Nikhil, Thakurta, Anjan, Morgan, Gareth J.

“…Understanding the profile of oncogene and tumor suppressor gene mutations with their interactions and impact on the prognosis of multiple myeloma (MM) can…”
Get full text

Role of domain interactions in the aggregation of full-length immunoglobulin light chains by Rennella, Enrico, Morgan, Gareth J., Kelly, Jeffery W., Kay, Lewis E.

“…Amyloid light-chain (LC) amyloidosis is a protein misfolding disease in which the aggregation of an overexpressed antibody LC from a clonal plasma cell leads…”
Get full text

The impact of intra‐clonal heterogeneity on the treatment of multiple myeloma by Brioli, Annamaria, Melchor, Lorenzo, Cavo, Michele, Morgan, Gareth J.

“…Summary It is clear that cancers comprise a mixture of clones, a feature termed intra‐clonal heterogeneity, that compete for spatial and nutritional resources…”
Get full text

International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials by Costa, Luciano J., Derman, Benjamin A., Bal, Susan, Sidana, Surbhi, Chhabra, Saurabh, Silbermann, Rebecca, Ye, Jing C., Cook, Gordon, Cornell, Robert F., Holstein, Sarah A., Shi, Qian, Omel, James, Callander, Natalie S., Chng, Wee Joo, Hungria, Vania, Maiolino, Angelo, Stadtmauer, Edward, Giralt, Sergio, Pasquini, Marcelo, Jakubowiak, Andrzej J., Morgan, Gareth J., Krishnan, Amrita, Jackson, Graham H., Mohty, Mohamad, Mateos, Maria Victoria, Dimopoulos, Meletious A., Facon, Thierry, Spencer, Andrew, Miguel, Jesus San, Hari, Parameswaran, Usmani, Saad Z., Manier, Salomon, McCarthy, Phillip, Kumar, Shaji, Gay, Francesca, Paiva, Bruno

“…Minimal residual disease (MRD) assessment is incorporated in an increasing number of multiple myeloma (MM) clinical trials as a correlative analysis, an…”
Get full text

Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma by Weinhold, Niels, Ashby, Cody, Rasche, Leo, Chavan, Shweta S., Stein, Caleb, Stephens, Owen W., Tytarenko, Ruslana, Bauer, Michael A., Meissner, Tobias, Deshpande, Shayu, Patel, Purvi H., Buzder, Timea, Molnar, Gabor, Peterson, Erich A., van Rhee, Frits, Zangari, Maurizio, Thanendrarajan, Sharmilan, Schinke, Carolina, Tian, Erming, Epstein, Joshua, Barlogie, Bart, Davies, Faith E., Heuck, Christoph J., Walker, Brian A, Morgan, Gareth J.

“…To elucidate the mechanisms underlying relapse from chemotherapy in multiple myeloma, we performed a longitudinal study of 33 patients entered into Total…”
Get full text

Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients by Weinhold, Niels, Salwender, Hans J, Cairns, David A, Raab, Marc S, Waldron, George, Blau, Igor W, Bertsch, Uta, Hielscher, Thomas, Morgan, Gareth J, Jauch, Anna, Davies, Faith E, Hänel, Mathias, Cook, Gordon, Scheid, Christoph, Houlston, Richard, Goldschmidt, Hartmut, Jackson, Graham, Kaiser, Martin F

Get full text

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study by RAWSTRON, Andy C, CHILD, J. Anthony, ROSS, Fiona M, COOK, Gordon, JACKSON, Graham H, MORGAN, Gareth J, OWEN, Roger G, DE TUTE, Ruth M, DAVIES, Faith E, GREGORY, Walter M, BELL, Sue E, SZUBERT, Alexander J, NAVARRO-COY, Nuria, DRAYSON, Mark T, FEYLER, Sylvia

“…To investigate the prognostic value of minimal residual disease (MRD) assessment in patients with multiple myeloma treated in the MRC (Medical Research…”
Get full text

Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma by Giles, Sharon L, Messiou, Christina, Collins, David J, Morgan, Veronica A, Simpkin, Catherine J, West, Sharon, Davies, Faith E, Morgan, Gareth J, deSouza, Nandita M

“…To determine the feasibility of whole-body diffusion-weighted (DW) magnetic resonance (MR) imaging for assessment of treatment response in myeloma. This…”
Get full text

The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma by Boyle, Eileen M., Deshpande, Shayu, Tytarenko, Ruslana, Ashby, Cody, Wang, Yan, Bauer, Michael A., Johnson, Sarah K., Wardell, Christopher P., Thanendrarajan, Sharmilan, Zangari, Maurizio, Facon, Thierry, Dumontet, Charles, Barlogie, Bart, Arbini, Arnaldo, Rustad, Even H., Maura, Francesco, Landgren, Ola, Zhan, Fenghuang, van Rhee, Frits, Schinke, Carolina, Davies, Faith E., Morgan, Gareth J., Walker, Brian A.

“…Smoldering myeloma (SMM) is associated with a high-risk of progression to myeloma (MM). We report the results of a study of 82 patients with both targeted…”
Get full text

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction by Rawstron, Andy C., Gregory, Walter M., de Tute, Ruth M., Davies, Faith E., Bell, Sue E., Drayson, Mark T., Cook, Gordon, Jackson, Graham H., Morgan, Gareth J., Child, J. Anthony, Owen, Roger G.

“…The detection of minimal residual disease (MRD) in myeloma using a 0.01% threshold (10−4) after treatment is an independent predictor of progression-free…”
Get full text

The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma XI’, a multicentre, open‐label, randomised, phase III trial by Jenner, Matthew W., Pawlyn, Charlotte, Davies, Faith E., Menzies, Tom, Hockaday, Anna, Olivier, Catherine, Jones, John R., Karunanithi, Kamaraj, Lindsay, Jindriska, Kishore, Bhuvan, Cook, Gordon, Drayson, Mark T., Kaiser, Martin F., Owen, Roger G., Gregory, Walter, Cairns, David A., Morgan, Gareth J., Jackson, Graham H.

“…Summary Lenalidomide is an effective maintenance agent for patients with myeloma, prolonging first remission and, in transplant eligible patients, improving…”
Get full text

Mutational Status of the TP53 Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial by GONZALEZ, David, MARTINEZ, Pilar, WADE, Rachel, HOCKLEY, Sarah, OSCIER, David, MATUTES, Estella, DEARDEN, Claire E, RICHARDS, Sue M, CATOVSKY, Daniel, MORGAN, Gareth J

“…TP53 mutations have been described in chronic lymphocytic leukemia (CLL) and have been associated with poor prognosis in retrospective studies. We aimed to…”
Get full text

Incomplete Refolding of Antibody Light Chains to Non-Native, Protease-Sensitive Conformations Leads to Aggregation: A Mechanism of Amyloidogenesis in Patients? by Morgan, Gareth J, Usher, Grace A, Kelly, Jeffery W

“…Genetic, biochemical, and pharmacologic evidence supports the hypothesis that conformationally altered or misfolded protein states enable aggregation and…”
Get full text

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM) by Mateos, María-Victoria, Kumar, Shaji, Dimopoulos, Meletios A., González-Calle, Verónica, Kastritis, Efstathios, Hajek, Roman, De Larrea, Carlos Fernández, Morgan, Gareth J., Merlini, Giampaolo, Goldschmidt, Hartmut, Geraldes, Catarina, Gozzetti, Alessandro, Kyriakou, Charalampia, Garderet, Laurent, Hansson, Markus, Zamagni, Elena, Fantl, Dorotea, Leleu, Xavier, Kim, Byung-Su, Esteves, Graça, Ludwig, Heinz, Usmani, Saad, Min, Chang-Ki, Qi, Ming, Ukropec, Jon, Weiss, Brendan M., Rajkumar, S. Vincent, Durie, Brian G. M., San-Miguel, Jesús

“…Smoldering multiple myeloma (SMM) is an asymptomatic precursor state of multiple myeloma (MM). Recently, MM was redefined to include biomarkers predicting a…”
Get full text

The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states by Rasche, Leo, Schinke, Carolina, Maura, Francesco, Bauer, Michael A., Ashby, Cody, Deshpande, Shayu, Poos, Alexandra M., Zangari, Maurizio, Thanendrarajan, Sharmilan, Davies, Faith E., Walker, Brian A., Barlogie, Bart, Landgren, Ola, Morgan, Gareth J., van Rhee, Frits, Weinhold, Niels

“…Deciphering Multiple Myeloma evolution in the whole bone marrow is key to inform curative strategies. Here, we perform spatial-longitudinal whole-exome…”
Get full text